MRI fused with prone FDG PET/CT improves the primary tumour staging of patients with breast cancer.

Autor: Garcia-Velloso MJ; Department of Nuclear Medicine, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Spain. mjgarciave@unav.es., Ribelles MJ; Department of Nuclear Medicine, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Spain., Rodriguez M; Department of Nuclear Medicine, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Spain., Fernandez-Montero A; Department of Occupational Medicine, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Spain., Sancho L; Department of Nuclear Medicine, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Spain., Prieto E; Department of Nuclear Medicine, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Spain., Santisteban M; Department of Oncology, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Spain., Rodriguez-Spiteri N; Department of Surgery, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Spain., Idoate MA; Department of Pathology, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Spain., Martinez-Regueira F; Department of Surgery, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Spain., Elizalde A; Department of Radiology, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Spain., Pina LJ; Department of Radiology, Clinica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Spain.
Jazyk: angličtina
Zdroj: European radiology [Eur Radiol] 2017 Aug; Vol. 27 (8), pp. 3190-3198. Date of Electronic Publication: 2016 Dec 21.
DOI: 10.1007/s00330-016-4685-8
Abstrakt: Objective: Our aim was to evaluate the diagnostic accuracy of magnetic resonance imaging (MRI) fused with prone 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) in primary tumour staging of patients with breast cancer.
Methods: This retrospective study evaluated 45 women with 49 pathologically proven breast carcinomas. MRI and prone PET-CT scans with time-of-flight and point-spread-function reconstruction were performed with the same dedicated breast coil. The studies were assessed by a radiologist and a nuclear medicine physician, and evaluation of fused images was made by consensus. The final diagnosis was based on pathology (90 lesions) or follow-up ≥ 24 months (17 lesions).
Results: The study assessed 72 malignant and 35 benign lesions with a median size of 1.8 cm (range 0.3-8.4 cm): 31 focal, nine multifocal and nine multicentric cases. In lesion-by-lesion analysis, sensitivity, specificity, positive and negative predictive values were 97%, 80%, 91% and 93% for MRI, 96%, 71%, 87%, and 89% for prone PET, and 97%. 94%, 97% and 94% for MRI fused with PET. Areas under the curve (AUC) were 0.953, 0.850, and 0.983, respectively (p < 0.01).
Conclusions: MRI fused with FDG-PET is more accurate than FDG-PET in primary tumour staging of breast cancer patients and increases the specificity of MRI.
Key Points: • FDG PET-CT may improve the specificity of MRI in breast cancer staging. • MRI fused with prone 2-[fluorine-18]-fluoro-2-deoxy-D-glucose PET-CT has better overall diagnostic performance than MRI. • The clinical role of fused PET-MRI has not yet been established.
Databáze: MEDLINE
Externí odkaz: